Massive malaria vaccine trial shows promise for protecting children
NCT ID NCT03855995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the RTS,S/AS01E malaria vaccine in nearly 78,000 young children in Sub-Saharan Africa. Researchers checked the vaccine's safety and how well it prevents malaria. The goal was to see if the vaccine can be safely used in routine immunization programs to protect children from this deadly disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Kintampo, Ghana
-
GSK Investigational Site
Navrongo, Ghana
-
GSK Investigational Site
Kisumu, 4 0100, Kenya
-
GSK Investigational Site
Kisumu, 40100, Kenya
-
GSK Investigational Site
Chikwawa, Malawi
-
GSK Investigational Site
Mangochi, Malawi
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill make your blood deadly to malaria mosquitoes?
- Can a new vaccine stop malaria in its tracks?
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- One shot, six months of malaria shield? a new trial tests a powerful antibody in children
- School health rooms and trained teachers: a new hope for Zambia's children?
- Experimental malaria vaccine aims to block parasite growth